274 related articles for article (PubMed ID: 29147793)
21. Rational discovery of dengue type 2 non-competitive inhibitors.
Heh CH; Othman R; Buckle MJ; Sharifuddin Y; Yusof R; Rahman NA
Chem Biol Drug Des; 2013 Jul; 82(1):1-11. PubMed ID: 23421589
[TBL] [Abstract][Full Text] [Related]
22. Discovery and SAR studies of methionine-proline anilides as dengue virus NS2B-NS3 protease inhibitors.
Zhou GC; Weng Z; Shao X; Liu F; Nie X; Liu J; Wang D; Wang C; Guo K
Bioorg Med Chem Lett; 2013 Dec; 23(24):6549-54. PubMed ID: 24268549
[TBL] [Abstract][Full Text] [Related]
23. Use of parallel validation high-throughput screens to reduce false positives and identify novel dengue NS2B-NS3 protease inhibitors.
Tomlinson SM; Watowich SJ
Antiviral Res; 2012 Feb; 93(2):245-252. PubMed ID: 22193283
[TBL] [Abstract][Full Text] [Related]
24. Novel dengue virus NS2B/NS3 protease inhibitors.
Wu H; Bock S; Snitko M; Berger T; Weidner T; Holloway S; Kanitz M; Diederich WE; Steuber H; Walter C; Hofmann D; Weißbrich B; Spannaus R; Acosta EG; Bartenschlager R; Engels B; Schirmeister T; Bodem J
Antimicrob Agents Chemother; 2015 Feb; 59(2):1100-9. PubMed ID: 25487800
[TBL] [Abstract][Full Text] [Related]
25. Structural Insights into the Inhibition of Zika Virus NS2B-NS3 Protease by a Small-Molecule Inhibitor.
Li Y; Zhang Z; Phoo WW; Loh YR; Li R; Yang HY; Jansson AE; Hill J; Keller TH; Nacro K; Luo D; Kang C
Structure; 2018 Apr; 26(4):555-564.e3. PubMed ID: 29526431
[TBL] [Abstract][Full Text] [Related]
26. Dengue Virus NS2B/NS3 Protease Inhibitors Exploiting the Prime Side.
Lin KH; Ali A; Rusere L; Soumana DI; Kurt Yilmaz N; Schiffer CA
J Virol; 2017 May; 91(10):. PubMed ID: 28298600
[TBL] [Abstract][Full Text] [Related]
27. Discovery of novel cyclic peptide inhibitors of dengue virus NS2B-NS3 protease with antiviral activity.
Takagi Y; Matsui K; Nobori H; Maeda H; Sato A; Kurosu T; Orba Y; Sawa H; Hattori K; Higashino K; Numata Y; Yoshida Y
Bioorg Med Chem Lett; 2017 Aug; 27(15):3586-3590. PubMed ID: 28539222
[TBL] [Abstract][Full Text] [Related]
28. Proline-Based Allosteric Inhibitors of Zika and Dengue Virus NS2B/NS3 Proteases.
Millies B; von Hammerstein F; Gellert A; Hammerschmidt S; Barthels F; Göppel U; Immerheiser M; Elgner F; Jung N; Basic M; Kersten C; Kiefer W; Bodem J; Hildt E; Windbergs M; Hellmich UA; Schirmeister T
J Med Chem; 2019 Dec; 62(24):11359-11382. PubMed ID: 31769670
[TBL] [Abstract][Full Text] [Related]
29. Computational screening of medicinal plant phytochemicals to discover potent pan-serotype inhibitors against dengue virus.
Tahir Ul Qamar M; Maryam A; Muneer I; Xing F; Ashfaq UA; Khan FA; Anwar F; Geesi MH; Khalid RR; Rauf SA; Siddiqi AR
Sci Rep; 2019 Feb; 9(1):1433. PubMed ID: 30723263
[TBL] [Abstract][Full Text] [Related]
30. Structure activity relationship (SAR) and quantitative structure activity relationship (QSAR) studies showed plant flavonoids as potential inhibitors of dengue NS2B-NS3 protease.
Sarwar MW; Riaz A; Dilshad SMR; Al-Qahtani A; Nawaz-Ul-Rehman MS; Mubin M
BMC Struct Biol; 2018 Apr; 18(1):6. PubMed ID: 29673347
[TBL] [Abstract][Full Text] [Related]
31. Towards the design of antiviral inhibitors against flaviviruses: the case for the multifunctional NS3 protein from Dengue virus as a target.
Lescar J; Luo D; Xu T; Sampath A; Lim SP; Canard B; Vasudevan SG
Antiviral Res; 2008 Nov; 80(2):94-101. PubMed ID: 18674567
[TBL] [Abstract][Full Text] [Related]
32. Anthracene-based inhibitors of dengue virus NS2B-NS3 protease.
Tomlinson SM; Watowich SJ
Antiviral Res; 2011 Feb; 89(2):127-35. PubMed ID: 21185332
[TBL] [Abstract][Full Text] [Related]
33. Antiviral activities of 15 dengue NS2B-NS3 protease inhibitors using a human cell-based viral quantification assay.
Chu JJ; Lee RC; Ang MJ; Wang WL; Lim HA; Wee JL; Joy J; Hill J; Brian Chia CS
Antiviral Res; 2015 Jun; 118():68-74. PubMed ID: 25823617
[TBL] [Abstract][Full Text] [Related]
34. Simultaneous uncoupled expression and purification of the Dengue virus NS3 protease and NS2B co-factor domain.
Shannon AE; Chappell KJ; Stoermer MJ; Chow SY; Kok WM; Fairlie DP; Young PR
Protein Expr Purif; 2016 Mar; 119():124-9. PubMed ID: 26647367
[TBL] [Abstract][Full Text] [Related]
35. Identification of novel and potential inhibitors against the dengue virus NS2B/NS3 protease using virtual screening and biomolecular simulations.
Nasir A; Samad A; Ajmal A; Li P; Islam M; Ullah S; Shah M; Bai Q
Int J Biol Macromol; 2024 Jun; 272(Pt 1):132855. PubMed ID: 38834129
[TBL] [Abstract][Full Text] [Related]
36. NS2B-NS3 protease inhibitors as promising compounds in the development of antivirals against Zika virus: A systematic review.
Nunes DAF; Santos FRDS; da Fonseca STD; de Lima WG; Nizer WSDC; Ferreira JMS; de Magalhães JC
J Med Virol; 2022 Feb; 94(2):442-453. PubMed ID: 34636434
[TBL] [Abstract][Full Text] [Related]
37. Erythrosin B is a potent and broad-spectrum orthosteric inhibitor of the flavivirus NS2B-NS3 protease.
Li Z; Sakamuru S; Huang R; Brecher M; Koetzner CA; Zhang J; Chen H; Qin CF; Zhang QY; Zhou J; Kramer LD; Xia M; Li H
Antiviral Res; 2018 Feb; 150():217-225. PubMed ID: 29288700
[TBL] [Abstract][Full Text] [Related]
38. 3D-QSAR pharmacophore-based virtual screening, molecular docking and molecular dynamics simulation toward identifying lead compounds for NS2B-NS3 protease inhibitors.
Luo PH; Zhang XR; Huang L; Yuan L; Zhou XZ; Gao X; Li LS
J Recept Signal Transduct Res; 2017 Oct; 37(5):481-492. PubMed ID: 28758854
[TBL] [Abstract][Full Text] [Related]
39. Conformational flexibility of DENV NS2B/NS3pro: from the inhibitor effect to the serotype influence.
Piccirillo E; Merget B; Sotriffer CA; do Amaral AT
J Comput Aided Mol Des; 2016 Mar; 30(3):251-70. PubMed ID: 26923377
[TBL] [Abstract][Full Text] [Related]
40. 3D-QSAR and molecular docking studies of peptide-hybrids as dengue virus NS2B/NS3 protease inhibitors.
Jitonnom J; Meelua W; Tue-Nguen P; Saparpakorn P; Hannongbua S; Chotpatiwetchkul W
Chem Biol Interact; 2024 Jun; 396():111040. PubMed ID: 38735453
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
